Founded by a Brown University professor, Aingeal LLC is structured around addressing neurological disorders that affect synaptic plasticity and cognition - usefully understood as disorders on the autism spectrum, psychiatric and traumatic brain injuries. Though to date having what appears to be a very low profile, it is suggested that the effort is to make progress towards new forms of treatments to address cognitive deficits associated with psychiatric and neurodegenerative disorders. With therapeutics focused on indications to include Angelman Syndrome, major depressive disorder, autism, and traumatic brain injury, the firms principals have to date developed a prototypic new drug discovery platform that addresses enhancement of the activity of endogenous neurotrophins factors. Noting that current modalities have limited benefits while also often involving unacceptable side effects, the objective is to deliver medical breakthroughs where none currently exist.
